Topical Fenticonazole in Dermatology and Gynaecology

Background

Fenticonazole is an imidazole antifungal used topically for skin and vulvovaginal infections since the early 1980s. Unlike most imidazoles, it combines antimycotic activity with antibacterial and antiparasitic action against Trichomonas vaginalis, giving it a broader spectrum than typical single-target antifungals. This 2008 narrative review by Veraldi and Milani synthesized the clinical evidence accumulated over more than two decades of use, drawing on systematic MEDLINE, EMBASE, and AdisBase searches covering both dermatological and gynaecological indications.

The drug's mechanism works on three fronts: it inhibits Candida albicans' secretion of acid protease (a virulence factor linked to yeast adherence), damages the fungal cytoplasmic membrane, and blocks cytochrome oxidases and peroxidases. Fenticonazole is also active in vitro against Gram-positive bacteria and organisms associated with bacterial vaginosis, such as Gardnerella vaginalis and Mobiluncus spp., supporting its potential role in mixed infections.

Review Snapshot

Review type	Narrative literature review	Search period	1980 to 2007 (present at time of writing)
Studies included	24 dermatological; 17 gynaecological	Databases	MEDLINE, EMBASE, AdisBase
Dermatology focus	Superficial mycoses, tinea, pityriasis versicolor	Outcomes	Mycological/microbiological cure, clinical efficacy, tolerability
Gynaecology focus	Candidiasis, trichomoniasis, mixed infection, bacterial vaginosis	Comparators	Miconazole, clotrimazole, econazole, bifonazole, naftifine, placebo

Key Findings — Dermatology

Across 24 clinical studies (14 randomized/comparator-controlled, 10 open-label), fenticonazole 2% cream, spray, or powder produced mycological cure in up to 100% of patients with pityriasis versicolor and 95–96% of patients with tinea or candidal skin infections.
In a large open-label study (n = 760), the overall adverse event rate was under 4%, with discontinuation in roughly 1% of patients.
Head-to-head trials found fenticonazole at least as effective as miconazole, clotrimazole, econazole, bifonazole, naftifine, and cyclopyroxolamine, with several studies noting a faster onset of action.
Once-daily dosing (based on 72-hour skin retention in preclinical models) was associated with improved patient compliance compared with twice-daily regimens.

Key Findings — Gynaecology

Seventeen studies evaluated fenticonazole vaginal capsules, ovules, or cream across candidiasis, trichomoniasis, mixed infections, and bacterial vaginosis. The table below summarizes microbiological efficacy by indication.

Indication	Regimen (representative)	Studies	Microbiological efficacy
Vaginal candidiasis	600mg single dose to 200mg/day × 3 days (capsule/ovule); 2% cream	12	75–100% negative for Candida spp.; comparable to clotrimazole and miconazole
Vaginal trichomoniasis	600–1000mg single dose or daily × 2–5 days	3	28–65% negative for all organisms at day 7; 1000mg outperformed 600mg and placebo
Mixed infections	600mg single dose or 1000mg on days 1 and 3	2	45% negative for all organisms; 90–96% negative for C. albicans; 67–70% for T. vaginalis
Bacterial vaginosis	2% cream 5g daily × 7 days	1	85% cure vs 35% with placebo (p = 0.003)

Efficacy reflects eradication of the causative organism(s) on culture or microscopy at the study's primary assessment timepoint; ranges reflect variation across included studies and dose regimens.

Safety and Tolerability

Fenticonazole was well tolerated across both dermatological and gynaecological uses. On the skin, the most common adverse events were burning sensation and irritation, occurring in roughly 1–10% of patients depending on formulation, and rarely leading to discontinuation. With vaginal use, burning sensation was again the most frequently reported event (up to 7.3% of patients across pooled studies), though the review notes this symptom often overlapped with baseline symptoms of the vaginal infection itself rather than being clearly drug-induced. No systemic toxicity or major local tolerability concerns were identified across more than 20 years of clinical use.

Why This Matters for Practice

This review's central clinical argument is that fenticonazole's combined antifungal, antibacterial, and antiparasitic activity positions it as a convenient single-agent option for mixed infections — a category that traditionally required combining multiple topical agents, with attendant risks of resistance and cumulative local adverse effects. The authors point to fenticonazole's long track record, low cost relative to newer agents, and consistent tolerability profile as reasons for its continued relevance, even though it is one of the older imidazoles in clinical use.

At the same time, the review is a narrative synthesis of trials conducted mostly between the 1980s and mid-2000s, several of which are small, single-blind, or available only as English abstracts of non-English publications. The authors themselves call for larger, randomized trials specifically targeting mixed aetiology infections, an area they identify as of growing clinical relevance given an aging, increasingly co-morbid patient population.

Takeaway

Drawing on more than two decades and over 40 clinical studies, this review positions topical fenticonazole as a broad-spectrum, well-tolerated imidazole with demonstrated efficacy against dermatophytes, Candida spp., Trichomonas vaginalis, and bacteria implicated in vaginosis and superinfected skin mycoses. Its once-daily dosing and single-agent coverage of mixed infections offer practical advantages, though the authors emphasize that larger controlled trials in mixed-infection populations are still needed to confirm its role relative to newer agents.

Reference

Veraldi S, Milani R. Topical Fenticonazole in Dermatology and Gynaecology: Current Role in Therapy. Drugs. 2008;68(15):2183–2194.

Topical Fenticonazole in Dermatology and Gynaecology — Clinical Evidence Summary